Physician profile
William Craig
NPI 1811931694
$13,376.17
in general payments reported to CMS, 2019-2025
30 companies · $680 in 2025
The $680 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,996 · 2020: $1,477 · 2021: $1,586 · 2022: $2,185 · 2023: $2,468 · 2024: $2,985 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,884 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,884.03 |
| Education | $249.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,490.45 | 2019-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $2,428.47 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,338.60 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,042.66 | 2019-2025 | |
| Janssen Biotech, INC. | $954.94 | 2019-2025 | Tremfya |
| Pfizer INC. | $930.64 | 2019-2025 | |
| Lilly USA, LLC | $885.71 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $721.42 | 2019-2024 | Orencia |
| Glaxosmithkline, LLC. | $589.73 | 2019-2024 | Benlysta |
| Horizon Therapeutics Plc | $445.38 | 2019-2023 | Krystexxa |
| Radius Health, INC. | $235.80 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $205.86 | 2022-2024 | Saphnelo, Andexxa |
| Genentech USA, INC. | $193.42 | 2019-2024 | Actemra |
| Genzyme Corporation | $123.88 | 2019-2024 | |
| Organon LLC | $113.34 | 2023-2024 | Hadlima, Renflexis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $108.10 | 2023-2024 | Idacio |
| Sandoz INC. | $89.75 | 2023-2024 | Hyrimoz |
| Aurinia Pharma U.S., INC. | $71.18 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $61.28 | 2019-2024 | Strensiq |
| Mallinckrodt Hospital Products INC. | $58.69 | 2023-2024 | Acthar |
| Sobi, INC | $58.63 | 2019-2025 | |
| Celltrion USA INC. | $57.43 | 2023 | Yuflyma |
| Ani Pharmaceuticals, INC. | $49.74 | 2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $26.67 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $22.35 | 2024 | Arcalyst |
| Scilex Pharmaceuticals INC. | $18.75 | 2024 | |
| Ibsa Pharma INC. | $14.45 | 2023 | Tirosint, Licart |
| Mallinckrodt Enterprises LLC | $13.67 | 2019 | |
| Pacira Therapeutics, INC. | $13.21 | 2019 | |
| Daiichi Sankyo INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.